Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchFamotidineFamotidine (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19

Mather et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832
Aug 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 61% Improvement Relative Risk Death/intubation 50% Famotidine for COVID-19  Mather et al.  Prophylaxis Is prophylaxis with famotidine beneficial for COVID-19? PSM retrospective 772 patients in the USA Lower mortality (p=0.004) and death/intubation (p=0.003) c19early.org Mather et al., American J. Gastroenter.., Aug 2020 Favorsfamotidine Favorscontrol 0 0.5 1 1.5 2+
Famotidine for COVID-19
26th treatment shown to reduce risk in October 2021, now with p = 0.00028 from 30 studies, recognized in 2 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
PSM retrospective 878 hospitalized patients in the USA, 83 with existing famotidine use, showing significantly lower mortality with treatment.
risk of death, 61.4% lower, HR 0.39, p = 0.004, treatment 83, control 689, propensity score matching, Cox proportional hazards.
risk of death/intubation, 50.5% lower, HR 0.49, p = 0.003, treatment 83, control 689, propensity score matching, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mather et al., 26 Aug 2020, retrospective, USA, peer-reviewed, 3 authors.
This PaperFamotidineAll
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19
MS. Jeffrey F Mather, PhD Richard L Seip, MD Raymond G Mckay
American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832
INTRODUCTION: To compare outcomes in patients hospitalized with coronavirus (COVID-19) receiving famotidine therapy with those not receiving famotidine.
Study Highlights WHAT IS KNOWN? 3 Despite multiple trials that are currently underway to investigate the safety and efficacy of a large number of possible therapeutic agents, no drug to date has been shown to reduce COVID-19 mortality. 3 It has been postulated that famotidine's effect is achieved via its antagonism or inverse agonism of the histamine-2 receptor, inferring that the SARS-CoV-2 infection that results in COVID-19 is at least partially mediated by pathological histamine release. COVID-19 Mather et al.
References
Anand, Ziebuhr, Wadhwani, Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs, Science
Borrell, New York clinical trial quietly tests heartburn remedy against coronavirus
Bourinbaiar, Fruhstorfer, The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: Identification of a new class of antiviral agents, Life Sci
Burde, Seifert, Buschauer, Histamine inhibits activation of human neutrophils and HL-60 leukemic cells via H2-receptors, Naunyn Schmiedebergs Arch Pharmacol
Caughey, Raymond, Wolters, Angiotensin II generation by mast cell alpha-and beta-chymases, Biochim Biophys Acta
Eliezer, Hautefort, Hamel, Sudden and complete olfactory loss of function as a possible symptom of COVID-19, JAMA Otolaryngol Head Neck Surg
Ezeamuzie, Philips, Histamine, 2) receptors mediate the inhibitory effect of histamine on human eosinophil degranulation, Br J Pharmacol
Flamand, Plante, Picard, Histamine-induced inhibition of leukotriene biosynthesis in human neutrophils: Involvement of the H2 receptor and cAMP, Br J Pharmacol
Freedberg, Conigliaro, Wang, Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study, Gastroenterology, doi:10.1053/j.gastro.2020.05.053
Giacomelli, Pezzati, Conti, Self-reported olfactory and taste disorders in SARS-CoV-2 patients: A cross-sectional study, Clin Infect Dis
Janowitz, Gablenz, Pattinson, Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: A case series, Gut
Kritas, Ronconi, Caraffa, Mast cells contribute to coronavirus-induced inflammation: New anti-inflammatory strategy, J Biol Regul Homeost Agents
Malone, Tisdall, Smith, COVID-19: famotidine, histamine, mast cells, and mechanisms, Preprint Res Sq, doi:10.21203/rs.3.rs-30934/v2
Marshall, Portales-Cervantes, Leong, Mast cell responses to viruses and pathogen products, Int J Mol Sci
Metcalfe, Baram, Mekori, Mast cells, Physiol Rev
Mukai, Tsai, Saito, Mast cells as sources of cytokines, chemokines, and growth factors, Immunol Rev
Rabier, Damon, Chanez, Inhibition by histamine of plateletactivating-factor-induced neutrophil chemotaxis in bronchial asthma, Int Arch Allergy Appl Immunol
Theoharides, Alysandratos, Angelidou, Mast cells and inflammation, Biochim Biophys Acta
Tian, Hu, Niu, Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer, J Thorac Oncol
Wadee, Anderson, Sher, In vitro effects of histamine on migration, Int Arch Allergy Appl Immunol
Wu, Liu, Yang, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm Sin B
{ 'indexed': {'date-parts': [[2022, 1, 19]], 'date-time': '2022-01-19T16:48:48Z', 'timestamp': 1642610928169}, 'reference-count': 20, 'publisher': 'Ovid Technologies (Wolters Kluwer Health)', 'issue': '10', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['Am J Gastroenterol'], 'published-print': {'date-parts': [[2020, 10]]}, 'DOI': '10.14309/ajg.0000000000000832', 'type': 'journal-article', 'created': {'date-parts': [[2020, 8, 26]], 'date-time': '2020-08-26T21:12:33Z', 'timestamp': 1598476353000}, 'page': '1617-1623', 'source': 'Crossref', 'is-referenced-by-count': 55, 'title': ['Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19'], 'prefix': '10.14309', 'volume': '115', 'author': [ {'given': 'Jeffrey F.', 'family': 'Mather', 'sequence': 'first', 'affiliation': []}, {'given': 'Richard L.', 'family': 'Seip', 'sequence': 'additional', 'affiliation': []}, {'given': 'Raymond G.', 'family': 'McKay', 'sequence': 'additional', 'affiliation': []}], 'member': '276', 'published-online': {'date-parts': [[2020, 8, 26]]}, 'reference': [ { 'key': 'R2-20210520', 'doi-asserted-by': 'crossref', 'article-title': 'Famotidine use is associated with improved clinical outcomes in ' 'hospitalized COVID-19 patients: A propensity score matched ' 'retrospective cohort study', 'author': 'Freedberg', 'year': '2020', 'journal-title': 'Gastroenterology', 'DOI': '10.1053/j.gastro.2020.05.053'}, { 'key': 'R3-20210520', 'first-page': '1', 'article-title': 'Famotidine use and quantitative symptom tracking for COVID-19 in ' 'non-hospitalised patients: A case series', 'volume': '0', 'author': 'Janowitz', 'year': '2020', 'journal-title': 'Gut'}, { 'issue': '23', 'key': 'R4-20210520', 'doi-asserted-by': 'crossref', 'first-page': '365', 'DOI': '10.1016/S0024-3205(96)00553-X', 'article-title': 'The effect of histamine type 2 receptor antagonists on human ' 'immunodeficiency virus (HIV) replication: Identification of a new class ' 'of antiviral agents', 'volume': '59', 'author': 'Bourinbaiar', 'year': '1996', 'journal-title': 'Life Sci'}, { 'key': 'R5-20210520', 'article-title': 'COVID-19: famotidine, histamine, mast cells, and mechanisms', 'author': 'Malone', 'year': '2020', 'journal-title': 'Preprint Res Sq'}, { 'issue': '5', 'key': 'R6-20210520', 'doi-asserted-by': 'crossref', 'first-page': '766', 'DOI': '10.1016/j.apsb.2020.02.008', 'article-title': 'Analysis of therapeutic targets for SARS-CoV-2 and discovery of ' 'potential drugs by computational methods', 'volume': '10', 'author': 'Wu', 'year': '2020', 'journal-title': 'Acta Pharm Sin B'}, { 'issue': '5626', 'key': 'R7-20210520', 'doi-asserted-by': 'crossref', 'first-page': '1763', 'DOI': '10.1126/science.1085658', 'article-title': 'Coronavirus main proteinase (3CLpro) structure: Basis for design of ' 'anti-SARS drugs', 'volume': '300', 'author': 'Anand', 'year': '2003', 'journal-title': 'Science'}, { 'issue': '1', 'key': 'R8-20210520', 'first-page': '9', 'article-title': 'Mast cells contribute to coronavirus-induced inflammation: New ' 'anti-inflammatory strategy', 'volume': '34', 'author': 'Kritas', 'year': '2020', 'journal-title': 'J Biol Regul Homeost Agents'}, { 'issue': '15', 'key': 'R9-20210520', 'doi-asserted-by': 'crossref', 'first-page': '889', 'DOI': '10.1093/cid/ciaa330', 'article-title': 'Self-reported olfactory and taste disorders in SARS-CoV-2 patients: A ' 'cross-sectional study', 'volume': '71', 'author': 'Giacomelli', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, { 'key': 'R10-20210520', 'doi-asserted-by': 'crossref', 'first-page': '674', 'DOI': '10.1001/jamaoto.2020.0832', 'article-title': 'Sudden and complete olfactory loss of function as a possible symptom of ' 'COVID-19', 'volume': '146', 'author': 'Eliezer', 'year': '2020', 'journal-title': 'JAMA Otolaryngol Head Neck Surg'}, { 'issue': '5', 'key': 'R11-20210520', 'doi-asserted-by': 'crossref', 'first-page': '700', 'DOI': '10.1016/j.jtho.2020.02.010', 'article-title': 'Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) ' 'pneumonia in two patients with lung cancer', 'volume': '15', 'author': 'Tian', 'year': '2020', 'journal-title': 'J Thorac Oncol'}, { 'issue': '6', 'key': 'R12-20210520', 'doi-asserted-by': 'crossref', 'first-page': '671', 'DOI': '10.1007/BF00717743', 'article-title': 'Histamine inhibits activation of human neutrophils and HL-60 leukemic ' 'cells via H2-receptors', 'volume': '340', 'author': 'Burde', 'year': '1989', 'journal-title': 'Naunyn Schmiedebergs Arch Pharmacol'}, { 'issue': '2-3', 'key': 'R13-20210520', 'doi-asserted-by': 'crossref', 'first-page': '314', 'DOI': '10.1159/000234967', 'article-title': 'Inhibition by histamine of platelet-activating-factor-induced ' 'neutrophil chemotaxis in bronchial asthma', 'volume': '89', 'author': 'Rabier', 'year': '1989', 'journal-title': 'Int Arch Allergy Appl Immunol'}, { 'issue': '4', 'key': 'R14-20210520', 'doi-asserted-by': 'crossref', 'first-page': '552', 'DOI': '10.1038/sj.bjp.0705654', 'article-title': 'Histamine-induced inhibition of leukotriene biosynthesis in human ' 'neutrophils: Involvement of the H2 receptor and cAMP', 'volume': '141', 'author': 'Flamand', 'year': '2004', 'journal-title': 'Br J Pharmacol'}, { 'issue': '3', 'key': 'R15-20210520', 'doi-asserted-by': 'crossref', 'first-page': '482', 'DOI': '10.1038/sj.bjp.0703556', 'article-title': '(2) receptors mediate the inhibitory effect of histamine on human ' 'eosinophil degranulation', 'volume': '131', 'author': 'Ezeamuzie', 'year': '2000', 'journal-title': 'Br J Pharmacol'}, { 'issue': '3', 'key': 'R16-20210520', 'doi-asserted-by': 'crossref', 'first-page': '322', 'DOI': '10.1159/000232643', 'article-title': 'In vitro effects of histamine on eosinophil migration', 'volume': '63', 'author': 'Wadee', 'year': '1980', 'journal-title': 'Int Arch Allergy Appl Immunol'}, { 'issue': '4', 'key': 'R17-20210520', 'doi-asserted-by': 'crossref', 'first-page': '1033', 'DOI': '10.1152/physrev.1997.77.4.1033', 'article-title': 'Mast cells', 'volume': '77', 'author': 'Metcalfe', 'year': '1997', 'journal-title': 'Physiol Rev'}, { 'issue': '1', 'key': 'R18-20210520', 'doi-asserted-by': 'crossref', 'first-page': '121', 'DOI': '10.1111/imr.12634', 'article-title': 'Mast cells as sources of cytokines, chemokines, and growth factors', 'volume': '282', 'author': 'Mukai', 'year': '2018', 'journal-title': 'Immunol Rev'}, { 'issue': '1', 'key': 'R19-20210520', 'doi-asserted-by': 'crossref', 'first-page': '21', 'DOI': '10.1016/j.bbadis.2010.12.014', 'article-title': 'Mast cells and inflammation', 'volume': '1822', 'author': 'Theoharides', 'year': '2012', 'journal-title': 'Biochim Biophys Acta'}, { 'issue': '17', 'key': 'R20-20210520', 'doi-asserted-by': 'crossref', 'first-page': '4241', 'DOI': '10.3390/ijms20174241', 'article-title': 'Mast cell responses to viruses and pathogen products', 'volume': '20', 'author': 'Marshall', 'year': '2019', 'journal-title': 'Int J Mol Sci'}, { 'issue': '1-2', 'key': 'R21-20210520', 'doi-asserted-by': 'crossref', 'first-page': '245', 'DOI': '10.1016/S0167-4838(00)00076-5', 'article-title': 'Angiotensin II generation by mast cell alpha- and beta-chymases', 'volume': '1480', 'author': 'Caughey', 'year': '2000', 'journal-title': 'Biochim Biophys Acta'}], 'container-title': ['American Journal of Gastroenterology'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://journals.lww.com/10.14309/ajg.0000000000000832', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 5, 20]], 'date-time': '2021-05-20T04:01:20Z', 'timestamp': 1621483280000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 8, 26]]}, 'references-count': 20, 'journal-issue': {'issue': '10', 'published-print': {'date-parts': [[2020]]}}, 'URL': 'http://dx.doi.org/10.14309/ajg.0000000000000832', 'relation': {}, 'ISSN': ['0002-9270', '1572-0241'], 'issn-type': [{'value': '0002-9270', 'type': 'print'}, {'value': '1572-0241', 'type': 'electronic'}], 'subject': ['Gastroenterology', 'Hepatology'], 'published': {'date-parts': [[2020, 8, 26]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit